Last $1.59 USD
Change Today -0.08 / -4.79%
Volume 27.7K
DYAI On Other Exchanges
As of 8:10 PM 07/11/14 All times are local (Market data is delayed by at least 15 minutes).

dyadic international inc (DYAI) Snapshot

Previous Close
Day High
Day Low
52 Week High
08/8/13 - $2.00
52 Week Low
01/15/14 - $1.25
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

dyadic international inc (DYAI) Related Bloomberg News

View More Bloomberg News

dyadic international inc (DYAI) Related Businessweek News

No Related Businessweek News Found

dyadic international inc (DYAI) Details

Dyadic International, Inc., a biotechnology company, discovers, develops, manufactures, and sells enzymes, proteins, peptides, and other bio-molecules for the bioenergy, biochemical, industrial enzyme, and biopharmaceutical industries. It primarily manufactures and sells liquid and dry enzyme products for use in the animal feed, pulp and paper, starch and alcohol, food and brewing, textiles, and bio fuels industries. The company utilizes an integrated technology platform based on its patented and proprietary C1 fungus technology, which enables the development and manufacture of various proteins and enzymes, as well as other biological products, such as antibodies, vaccines, proteins, and polypeptides for the biopharmaceutical industry. It also develops fungal strains that produce enzymes used in animal health and nutrition applications. The company has operations in the United States and the Netherlands. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.

39 Employees
Last Reported Date: 03/12/14
Founded in 1979

dyadic international inc (DYAI) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

dyadic international inc (DYAI) Key Developments

Dyadic Appoints Michael Tarnok to Board of Directors

Dyadic International, Inc. announced the appointment of Michael Tarnok to the company's Board of Directors. Mr. Tarnok will also serve on the company's audit and compensation committees. Mr. Tarnok has extensive experience in the pharmaceutical industry across many key areas including finance, operations and marketing. He is the current Chairman and former Interim CEO of Keryx Biopharmaceuticals, Inc., a biotechnology company focused on the development of therapeutics for renal disease. Prior to joining Keryx in 2007, Mr. Tarnok spent the majority of his career at Pfizer Inc., joining in 1989 as Director of Finance for U.S. Manufacturing. From 2000-2007, he served as Senior Vice President in Pfizer's U.S. Pharmaceuticals Division. Prior to joining Pfizer, he worked primarily in financial disciplines for ITT Rayonier, Inc., Celanese Corporation, and Olivetti Corporation of America. Mr. Tarnok earned an MBA in marketing from New York University and a Bachelors of Science in accounting from St. John's University. He also serves on the Board of the Global Health Counsel, a Washington, D.C.-based NGO.

Dyadic International, Inc., Annual General Meeting, Jun 25, 2014

Dyadic International, Inc., Annual General Meeting, Jun 25, 2014., at 10:00 US Eastern Standard Time. Location: Doubletree Hotel, 4431 PGA Boulevard,. Agenda: To elect two Class I directors to the Board of Directors to serve until the company's 2017 Annual Meeting of Stockholders or until their successors are duly elected and qualified; to ratify the appointment of Mayer Hoffman McCann P.C., as the company's independent registered public accounting firm for the year ending December 31, 2014; and to transact such other business as may properly come before the Annual Meeting or any adjournment or postponement thereof.

Dyadic International, Inc. Presents at World Congress on Industrial Biotechnology, May-12-2014

Dyadic International, Inc. Presents at World Congress on Industrial Biotechnology, May-12-2014 . Venue: Philadelphia, Pennsylvania, United States.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
DYAI:US $1.59 USD -0.08

DYAI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
EI du Pont de Nemours & Co $64.89 USD -0.05
Koninklijke DSM NV €50.24 EUR -0.30
Lonza Group AG SFr.93.15 CHF -1.45
Merck KGaA €63.96 EUR +0.28
Novozymes A/S kr273.10 DKK +2.40
View Industry Companies

Industry Analysis


Industry Average

Valuation DYAI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 3.2x
Price/Book 48.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 2.4x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DYADIC INTERNATIONAL INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at